Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tysabri Withdrawal Prompts Biogen Idec To Suspend Financial Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

Company plans to issue revised guidance in May after warning investors not to rely on previous financial forecasts. Announcement coincides with news that a third diagnosis of PML was discovered in a clinical trial for Tysabri.

You may also be interested in...



Tysabri Could Return To Market As “Niche” Drug, Analyst Says

Morgan Stanley report predicts sales of $500 mil. for Biogen Idec/Elan’s multiple sclerosis therapy if it returns to market. Analyst’s review shows additional safety signals.

Tysabri Could Return To Market As “Niche” Drug, Analyst Says

Morgan Stanley report predicts sales of $500 mil. for Biogen Idec/Elan’s multiple sclerosis therapy if it returns to market. Analyst’s review shows additional safety signals.

Tysabri Strength Of Effect Led To Accelerated Approval, FDA Review Shows

Review documents characterize Biogen Idec/Elan’s biologic as an “important advance” in multiple sclerosis, but note the accelerated pathway has not previously been used for MS therapy. FDA concludes Tysabri (natalizumab) is “an important advance” beyond other MS treatments, meriting approval on one-year data. Final two-year results support efficacy, but Tysabri’s return to market hinges on resolving safety issues.

Related Content

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel